<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1415">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142735</url>
  </required_header>
  <id_info>
    <org_study_id>054-2020</org_study_id>
    <nct_id>NCT05142735</nct_id>
  </id_info>
  <brief_title>Effects of NAC on Symptoms of CHR Patients</brief_title>
  <official_title>Effects of N-acetylcysteine on Psychosis-like Symptoms and a Neurophysiological Biomarker of the Clinical High Risk for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with&#xD;
      &quot;clinical high-risk&quot; (CHR) symptoms, which are like those of schizophrenia but less severe,&#xD;
      and providing psychiatric care to these individuals has been shown to help prevent psychosis.&#xD;
      Current medications used for CHR symptoms, however, are associated with substantial side&#xD;
      effect burden. Therefore, practice guidelines do not recommend current medications as routine&#xD;
      treatment for the CHR state, and there is a need to identify new treatments for this&#xD;
      condition.&#xD;
&#xD;
      Research suggests that abnormal brain oxidative stress may contribute to schizophrenia,&#xD;
      offering a potential novel treatment target in the CHR state. Oxidative stress is an excess&#xD;
      of free radicals, which are generated from normal metabolism and environmental exposures, and&#xD;
      can damage cells. Antioxidants in the body normally neutralize free radicals. Antioxidant&#xD;
      deficiency could result in excess oxidative stress that damages brain cells, leading to&#xD;
      schizophrenia. Recent studies suggest that N-acetylcysteine (NAC), a precursor of the most&#xD;
      abundant brain antioxidant, glutathione, may be a safe, well-tolerated treatment for&#xD;
      schizophrenia. In light of this, NAC may also reduce symptoms and brain abnormalities in CHR&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to examine the effect of NAC on psychosis-like symptoms in CHR patients.&#xD;
      Secondary aims are to examine the effect of NAC, in these patients, on the amplitude of the&#xD;
      mismatch negativity (MMN), an electroencephalographic event-related potential (ERP) response&#xD;
      to rare sounds among frequent ones; and the amplitude of the N400 semantic priming effect, an&#xD;
      ERP response to unexpected compared to expected meaningful stimuli (e.g., words, pictures);&#xD;
      both of which have been found to be reduced in both schizophrenia and the CHR state.&#xD;
&#xD;
      This will be a randomized, double-blind, placebo-controlled trial. Ninety CHR patients will&#xD;
      take either NAC 2000 mg orally or placebo, daily for 8 weeks. Psychosis-like symptoms will be&#xD;
      assessed at baseline, week 4 and week 8 using the Positive symptom score of the Scale of&#xD;
      Psychosis-Risk Symptoms in the Structured Interview for Psychosis-Risk Syndromes. MMN&#xD;
      amplitude and the N400 semantic priming effect will be measured at baseline and week 8. We&#xD;
      hypothesize that patients will have more improvement in psychosis-like symptoms, and greater&#xD;
      increases in MMN amplitudes and N400 semantic priming effects, after taking NAC vs. placebo.&#xD;
      If we find that NAC improves psychosis-like symptoms and/or these neurophysiological&#xD;
      biomarkers of the CHR state, this would support further research on NAC as a preventive&#xD;
      treatment against psychosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of NAC or placebo groups in parallel for the duration of the study. This will be a randomized, double-blind, placebo-controlled trial.&#xD;
Participants will be randomized to take either NAC 2000 mg or placebo, in the form of oral capsules, every morning for 8 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators and research staff are blinded to the conditions. Research Pharmacy staff are unblinded and responsible for randomization and NAC or placebo dispensing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in positive psychosis-like symptoms from baseline to 8 weeks</measure>
    <time_frame>Week 0 to week 8</time_frame>
    <description>Measured by the Positive symptom score of the Scale of Psychosis-Risk Symptoms, where the minimum score is 0 and the maximum score is 30, and higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mismatch negativity (MMN) amplitude from baseline to 8 weeks</measure>
    <time_frame>Week 0 to week 8</time_frame>
    <description>MMN amplitude will be measured as mean voltage from 135-205 ms post-stimulus onset of the ERP waveform formed by subtracting the average for standard tones from the average for deviant tones.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N400 semantic priming effect from baseline to 8 weeks</measure>
    <time_frame>Week 0 to week 8</time_frame>
    <description>N400 semantic priming effect will be measured as mean voltage from 300-500 ms post-stimulus onset of the ERP waveform formed by subtracting the average for related stimuli from the average for unrelated stimuli.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prodromal Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetylcysteine 2000 mg (4 x 500-mg tablets) orally every morning for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N-Acetylcysteine Placebo tablet matching N-Acetylcysteine orally every morning for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>2000 mg (4 x 500-mg tablets) every morning</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 placebo tablets every morning</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. meeting Criteria of Psychosis-Risk Syndromes (COPS) criteria on the Structured&#xD;
             Interview for Psychosis-Risk Syndromes (SIPS)&#xD;
&#xD;
          2. capacity to provide informed consent&#xD;
&#xD;
          3. if female, participant is not of child-bearing potential, defined as females who have&#xD;
             undergone a sterilization procedure or have been post-menopausal for at least 1 year&#xD;
             prior to screening OR participant is of child-bearing potential and agrees to use a&#xD;
             medically approved method of birth control for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. meeting criteria for any other DSM-5 diagnosis at the time of the study (except&#xD;
             -personality disorder, nicotine use disorder, or other substance use disorder in full&#xD;
             remission)&#xD;
&#xD;
          2. concomitant or past neurological condition&#xD;
&#xD;
          3. visual impairment which is not corrected to normal by prescription glasses history of&#xD;
             reading disability&#xD;
&#xD;
          4. past antipsychotic treatment at a therapeutic dose&#xD;
&#xD;
          5. current treatment with a psychotropic medication&#xD;
&#xD;
          6. pregnancy (as identified on self-report and/or rapid urine pregnancy test) or intent&#xD;
             to become pregnant according to self-report&#xD;
&#xD;
          7. breastfeeding or plan to do so&#xD;
&#xD;
          8. history of kidney stones&#xD;
&#xD;
          9. current treatment with an antibiotic&#xD;
&#xD;
         10. current treatment with nitroglycerin&#xD;
&#xD;
         11. allergy to any ingredients in either the investigational product or placebo product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kiang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kiang, MD, PhD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>30337</phone_ext>
    <email>michael.kiang@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenny Lepock, PhD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>34639</phone_ext>
    <email>jenny.lepock@camh.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Addington J, Addington D, Abidi S, Raedler T, Remington G. Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis. Can J Psychiatry. 2017 Sep;62(9):656-661. doi: 10.1177/0706743717719895. Epub 2017 Jul 21. Review.</citation>
    <PMID>28730848</PMID>
  </reference>
  <reference>
    <citation>Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol Psychiatry. 2012 Jan 15;71(2):98-104. doi: 10.1016/j.biopsych.2011.08.023. Epub 2011 Oct 13.</citation>
    <PMID>22000060</PMID>
  </reference>
  <reference>
    <citation>Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y, Francis MM. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018 Sep;199:395-402. doi: 10.1016/j.schres.2018.03.012. Epub 2018 Mar 24.</citation>
    <PMID>29588126</PMID>
  </reference>
  <reference>
    <citation>Cabungcal JH, Counotte DS, Lewis E, Tejeda HA, Piantadosi P, Pollock C, Calhoon GG, Sullivan E, Presgraves E, Kil J, Hong LE, Cuenod M, Do KQ, O'Donnell P. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014 Sep 3;83(5):1073-1084. doi: 10.1016/j.neuron.2014.07.028. Epub 2014 Aug 14.</citation>
    <PMID>25132466</PMID>
  </reference>
  <reference>
    <citation>Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, Ferrari C, Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Woo TW, Keshavan MS, Eap CB, Wojcik J, Cuenod M, Buclin T, Gruetter R, Do KQ. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophr Bull. 2018 Feb 15;44(2):317-327. doi: 10.1093/schbul/sbx093.</citation>
    <PMID>29462456</PMID>
  </reference>
  <reference>
    <citation>Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013 Sep 15;74(6):400-9. doi: 10.1016/j.biopsych.2013.03.018. Epub 2013 May 15.</citation>
    <PMID>23683390</PMID>
  </reference>
  <reference>
    <citation>Hsieh MH, Shan JC, Huang WL, Cheng WC, Chiu MJ, Jaw FS, Hwu HG, Liu CC. Auditory event-related potential of subjects with suspected pre-psychotic state and first-episode psychosis. Schizophr Res. 2012 Sep;140(1-3):243-9. doi: 10.1016/j.schres.2012.06.021. Epub 2012 Jul 10.</citation>
    <PMID>22784684</PMID>
  </reference>
  <reference>
    <citation>Jahshan C, Cadenhead KS, Rissling AJ, Kirihara K, Braff DL, Light GA. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol Med. 2012 Jan;42(1):85-97. doi: 10.1017/S0033291711001061. Epub 2011 Jul 11.</citation>
    <PMID>21740622</PMID>
  </reference>
  <reference>
    <citation>Kim M, Lee TH, Yoon YB, Lee TY, Kwon JS. Predicting Remission in Subjects at Clinical High Risk for Psychosis Using Mismatch Negativity. Schizophr Bull. 2018 Apr 6;44(3):575-583. doi: 10.1093/schbul/sbx102.</citation>
    <PMID>29036493</PMID>
  </reference>
  <reference>
    <citation>Lavoie S, Jack BN, Griffiths O, Ando A, Amminger P, Couroupis A, Jago A, Markulev C, McGorry PD, Nelson B, Polari A, Yuen HP, Whitford TJ. Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis. Schizophr Res. 2018 Jan;191:95-100. doi: 10.1016/j.schres.2017.11.005. Epub 2017 Nov 11.</citation>
    <PMID>29132815</PMID>
  </reference>
  <reference>
    <citation>Lepock JR, Ahmed S, Mizrahi R, Gerritsen CJ, Maheandiran M, Drvaric L, Bagby RM, Korostil M, Light GA, Kiang M. Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis. Schizophr Res. 2020 Dec;226:84-94. doi: 10.1016/j.schres.2019.01.014. Epub 2019 Jan 22.</citation>
    <PMID>30683525</PMID>
  </reference>
  <reference>
    <citation>Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-15. Erratum in: Schizophr Bull. 2004;30(2):following 217.</citation>
    <PMID>14989408</PMID>
  </reference>
  <reference>
    <citation>Nagai T, Tada M, Kirihara K, Yahata N, Hashimoto R, Araki T, Kasai K. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis. Schizophr Res. 2013 Nov;150(2-3):547-54. doi: 10.1016/j.schres.2013.08.005. Epub 2013 Sep 6.</citation>
    <PMID>24012461</PMID>
  </reference>
  <reference>
    <citation>Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, Mathalon DH. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry. 2014 Mar 15;75(6):459-69. doi: 10.1016/j.biopsych.2013.07.038. Epub 2013 Sep 16.</citation>
    <PMID>24050720</PMID>
  </reference>
  <reference>
    <citation>Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015 Mar;30(3):388-404. doi: 10.1016/j.eurpsy.2015.01.013. Epub 2015 Mar 3.</citation>
    <PMID>25749390</PMID>
  </reference>
  <reference>
    <citation>Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:289-296. doi: 10.1016/j.pnpbp.2017.11.001. Epub 2017 Nov 7.</citation>
    <PMID>29126981</PMID>
  </reference>
  <reference>
    <citation>Shaikh M, Valmaggia L, Broome MR, Dutt A, Lappin J, Day F, Woolley J, Tabraham P, Walshe M, Johns L, Fusar-Poli P, Howes O, Murray RM, McGuire P, Bramon E. Reduced mismatch negativity predates the onset of psychosis. Schizophr Res. 2012 Jan;134(1):42-8. doi: 10.1016/j.schres.2011.09.022. Epub 2011 Oct 24.</citation>
    <PMID>22024244</PMID>
  </reference>
  <reference>
    <citation>Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M, Do KQ. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A &quot;central hub&quot; in schizophrenia pathophysiology? Schizophr Res. 2016 Sep;176(1):41-51. doi: 10.1016/j.schres.2014.06.021. Epub 2014 Jul 5. Review.</citation>
    <PMID>25000913</PMID>
  </reference>
  <reference>
    <citation>Zheng W, Zhang QE, Cai DB, Yang XH, Qiu Y, Ungvari GS, Ng CH, Berk M, Ning YP, Xiang YT. N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2018 May;137(5):391-400. doi: 10.1111/acps.12862. Epub 2018 Feb 18.</citation>
    <PMID>29457216</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychosis</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>prodrome</keyword>
  <keyword>mismatch negativity</keyword>
  <keyword>event-related potentials</keyword>
  <keyword>clinical high risk state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

